Bradykinin B2 receptors as a target in diabetic nephropathy

Current Opinion in Investigational Drugs

Volumn 7, Issue 3, 2006, Pages 251-255

  Doggrell, Sheila A ^a  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

Angiotensin converting enzyme inhibitors; AVE 7688; Bradykinin B2 receptor; Diabetic nephropathy; Vasopeptidase inhibition

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; ALBUMIN; ANATIBANT; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; AVE 7688; BENAZEPRIL; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; GLUCOSE TRANSPORTER 4; ICATIBANT; KALLIKREIN; KININOGEN; LABRADIMIL; LISINOPRIL; N(G) NITROARGININE METHYL ESTER; NATRIURETIC FACTOR; OMAPATRILAT; PERINDOPRIL; RAMIPRIL; STREPTOZOCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VASOPEPTIDASE INHIBITOR; BRADYKININ B2 RECEPTOR; FUSED HETEROCYCLIC RINGS; PRODRUG; PROTEINASE INHIBITOR;

BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE MODEL; DISEASE SEVERITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; GENE MUTATION; GENE TARGETING; GENETIC CODE; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCOGEN METABOLISM; HEART FUNCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER PROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREDICTION; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STREPTOZOCIN DIABETES; STRUCTURE ANALYSIS; URINARY EXCRETION; VASODILATATION; ANIMAL; CHEMISTRY; CONFORMATION; METABOLISM;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETIC NEPHROPATHIES; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MOLECULAR CONFORMATION; PRODRUGS; PROTEASE INHIBITORS; RECEPTOR, BRADYKININ B2;

EID: 33644939942     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Margolius HS: Kallikreins and kinins - some unanswered questions about system characteristics and roles in human disease. Hypertension (1995) 26(2):221-229.
2. 2 receptor in rat kidney by anti-peptide and anti-ligand antibodies. J Histochem Cytochem (1995) 43(2):137-148.
3. Damas J, Garbacki N, Lefèbvre PJ: The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. Diabetes Metab Res Rev (2004) 20(4):288-297.
4. 2 receptor gene. Biochem Biophys Res Commun (1995) 211(1):234-240.
5. 2 receptor gene polymorphism is associated with altered urinary albumin/creatinine values in diabetic patients. Can J Physiol Pharmacol (2002) 80(4):323-327.
6. Zychma MJ, Gumprecht J, Trautsolt W, Szydlowska I, Grzeszczak W: Polymorphic genes for kinin receptors, nephropathy and blood pressure in type 2 diabetic patients. Am J Nephrol (2003) 23(2):112-116.
7. Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G, Alhenc-Gelas F, Marre M: Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: A prospective study. J Am Soc Nephrol (2001) 12(3):541-549.
8. Fava S, Azzopardi J, Ellard S, Hattersley AT: ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease. Diabetes Care (2001) 24(12):2115-2120.
9. Doggrell SA: Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? Expert Opin Pharmacother (2002) 3(11):1543-1556.
10. Jacobsen P, Andersen S, Jensen BR, Parving H-H: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol (2003) 14(4):992-999.
11. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. Br Med J (2000) 321(7274):1440-1444.
12. Andersen NH, Poulson PI, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW, Hellenberg K, Morgensen CE: Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: The CALM II study. Diabetes Care (2005) 28(2):273-277.
13. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideara T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet (2003) 361 (9352):117-124.
14. Huang W, Gallois Y, Bouby N, Bruneval P, Heudes D, Belair M-F, Krege JH, Meneton P, Marre M, Smithies O, Alhenc-Gelas F: Genetically increased angiotensin 1-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA (2001) 98(23): 13330-13334.
15. 2 receptor of bradykinin in insulin sensitivity. Hypertension (2001) 38(6):1355-1360.
16. 2 receptor. Proc Natl Acad Sci USA (2004) 101(36):13302-13305.
17. Harvey JN, Edmundson AW, Jaffa AA, Martin LL, Mayfield RK: Renal excretion of kallikrein and eicosanoids in patients with type 1 (insulin-dependent) diabetes mellitus. Relationship to glomerular and tubular function. Diabetologia (1992) 35(9):857-862.
18. Henriksen EJ, Jacob S: Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes Metab (2003) 5(4):214-222.
19. Montanari D, Yin H, Dobrzyski E, Agata J, Yoshida H, Chao J, Chao L: Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes (2005) 54(5): 1573-1580.
20. Vora JP, Oyama U, Thompson MM, Anderson S: interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes. Diabetes (1997) 46(1):107-112.
21. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME: Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Diabetes (1997) 46(10):1612-1618.
22. Tschöpe C, Seidl U, Reinecke A, Riester U, Graf K, Schuitheiss H-P, Hilgenfeldt U, Unger T: Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy. Int Immunopharmacol (2003) 3(3):335-344.
23. Taal MW, Nenov VD, Wong W, Satyal SR, Sakharova O, Choi JH, Troy JL, Brenner BM: Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol (2001) 12(10):2051-2059.
24. Zhou X, Ono H, Ono Y, Frohlich ED: Renoprotective effects of omapatrilat are mediated partially by bradykinin. Am J Nephrol (2003) 23(4):214-221.
25. Tikkanen T, Tikkanen I, Rockwell MD, Allen TJ, Johnston CI, Cooper ME, Burrell LM: Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension (1998) 32(4):778-785.
26. Davis BJ, Johnstone CI, Burrell LM, Bums WC, Kubota E, Cao Z, Cooper ME, Allen TJ: Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia (2003) 46(7):961-971.
27. Schäfer S, Linz W, Bube A, Gerl M, Huber J, Kürzel GU, Bleich M, Schmidts H-L, Busch AE, Rütten H: Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty acids. Cardiovasc Res (2003) 60(2):447-454.
28. Schäfer S, Linz W, Vollert H, Biemer-Daub G, Rütten H, Bleich M, Busch AE: The vasopeptidase inhibitor AVE7688 ameliorates type 2 diabetic nephropathy. Diabetiologia (2004) 47(1):98-103.
29. 2 receptor dependent. Br J Pharmacol (2004) 143(1):27-32.
30. Marceau F, Regoli D: Bradykinin receptor ligands: Therapeutic perspectives. Nat Rev Drug Discov (2004) 3(10):845-852.
31. 2 receptor. Curr Med Chem (2002) 9(9):913-928.